Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study.

Paolo Ragonese, Massimiliano Calabrese, Mariemma Rodegher, Mariangela D'Onghia, Marta Radaelli, Pietro Annovazzi, Antonio Gallo, Giovanni Frisullo, Valentina Tomassini, Damiano Paolicelli, Simona Malucchi, Viviana Nociti, Claudio Solaro, Claudio Gasperini, Carla Tortorella

Risultato della ricerca: Articlepeer review

6 Citazioni (Scopus)

Abstract

Few long-term follow-up data are available on thyroid dysfunction (TD) in multiple sclerosis (MS) patients treated with glatiramer acetate (GA) or with interferon-beta (IFNb). In a cohort of 787 relapsing-remitting MS (RRMS) patients whom were followed up for 8 years, we observed an increased prevalence of TD and thyroid autoimmunity (TA) within the first year of IFNb treatment, regardless of the dose or frequency of administration, while no change was observed with GA treatment. The increased prevalence of TD and TA within the first year of IFNb treatment suggested the need for close monitoring of thyroid function and autoimmunity, though only during the first year of IFNb treatment.
Lingua originaleEnglish
pagine (da-a)1265-1268
Numero di pagine4
RivistaMultiple Sclerosis
Volume20
Stato di pubblicazionePublished - 2014

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Fingerprint Entra nei temi di ricerca di 'Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study.'. Insieme formano una fingerprint unica.

Cita questo